Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pomalidomide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-22 of 22 for your search:
Start Over
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MF-002, 2010-018965-42, NCT01178281
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MM-003/C, 2010-023343-16, NCT01324947
CC-4047 in Treating Patients With Myelofibrosis
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC078B, P30CA015083, NCI-2009-01331, 07-005317, PO-MMM-PI-0007, MAYO-MC078B, NCT00669578
CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GI 105, PO-PANC-PI-009, NCT00540579
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MM-002, NCT00833833
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PO0023, 2009-014850-13, NCT01166113
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16705, PO-MM-PI-0039, NCT01432600
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-PC-002, NCT00072722
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MMM-001, NCT00463385
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000574742, P30CA015083, 07-003064, NCI-2009-01283, MC0789, MAYO-MC0789, NCT00558896
Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
Phase: Phase II
Type: Treatment
Status: Closed
Age: 50 and over
Sponsor: Other
Protocol IDs: MPN-SG 01-09, NCT00949364
IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: 2009_28/0924, 2009-013319-36, NCT01053949
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2010-01, NCT01177735
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: HIC 1011007607, NCT01319422
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: 2010_52, 2011-002081-20, NCT01745640
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MM-011, NCT02011113
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE4Y06, P30CA043703, NCT00482521
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-007, PO-WM-PI-0005, NCT01078974
Pomalidomide for Relapse/Refractory Waldenstrom's
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0972, NCI-2012-01882, NCT01198067
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MM-005, NCT01497093
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-MM-004, NCT01568294
Start Over